<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297944</url>
  </required_header>
  <id_info>
    <org_study_id>16-0260-F6A</org_study_id>
    <secondary_id>R36DA043714-01A1</secondary_id>
    <nct_id>NCT03297944</nct_id>
  </id_info>
  <brief_title>Sedative-Anxiolytic Effects on Simulated Driving Performance</brief_title>
  <official_title>Alprazolam and Simulated Driving Performance: Next Day Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marion Coe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of anxiety drugs taken at night on the ability to drive a car
      the next day. Participants will receive alprazolam, placebo, or zolpidem at night before bed
      or in the morning before using a driving simulator to assess impairment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>standard deviation of lane position</measure>
    <time_frame>16 hours</time_frame>
    <description>measure of swerving on the driving simulator</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psychomotor Impairment</condition>
  <arm_group>
    <arm_group_label>2ALP/PLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg Alprazolam administered at night, placebo administered in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1ALP/PLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg Alprazolam administered at night, placebo administered in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5ALP/PLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg Alprazolam administered at night, placebo administered in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOL/PLC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg Zolpidem administered at night, placebo administered in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLC/PLC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered at night, placebo administered in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLC/ALP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo administered at night, 1mg alprazolam administered in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>0.5 to 2mg administered at night or in the morning</description>
    <arm_group_label>2ALP/PLC</arm_group_label>
    <arm_group_label>1ALP/PLC</arm_group_label>
    <arm_group_label>0.5ALP/PLC</arm_group_label>
    <arm_group_label>PLC/ALP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>10mg administered at night or in the morning</description>
    <arm_group_label>ZOL/PLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo administered at night and/or in the morning</description>
    <arm_group_label>PLC/PLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  valid driver's license

          -  english-speaking and literate

        Exclusion Criteria:

          -  using daily medication for chronic condition

          -  acute narrow angle glaucoma

          -  previous adverse experience with study drugs

          -  experiences motion sickness in response to driving simulator

          -  BMI &gt; 30

          -  women who are pregnant, lactating, or planning on becoming pregnant

          -  regular use of tobacco products

          -  current substance use disorder

          -  clinically significant ECG

          -  current ongoing psychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion Coe</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Coe</last_name>
    <phone>859-257-6488</phone>
    <email>marion.coe@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center on Drug and Alcohol Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Coe</last_name>
      <phone>859-257-6488</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Marion Coe</investigator_full_name>
    <investigator_title>Doctoral Candidate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

